Topics

Takeda's Ninlaro shows progression-free survival benefit in multiple myeloma

05:27 EST 8 Nov 2019 | Pharmafile

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line maintenance treatment of multiple myeloma in adult patients not treated with stem cell transplantation.

In a Phase 3 study incorporating 706 multiple myeloma patients who had completed 6-12 months of initial therapy and achieved a partial response or better, Ninlaro demonstrated a “statistically significant” improvement in progression free survival compared to placebo, meeting its primary endpoint.

read more

Original Article: Takeda's Ninlaro shows progression-free survival benefit in multiple myeloma

NEXT ARTICLE

More From BioPortfolio on "Takeda's Ninlaro shows progression-free survival benefit in multiple myeloma"

Quick Search

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...